Swedish Experiences of THA Therapy in Alzheimer’s Disease
As in other western countries the mean age of the population in Sweden is increasing steadily and the number of individuals over 65 is growing rapidly. The mean surviving age of Swedes has become among the highest in the world, now 75 for men and 80 for women. This means that psychiatric problems of old age, such as the dementia disorders, has become a common concern for the health care system as well as for the whole community. Alzheimer’s disease is the most prevalent dementing illness in the western world, responsible for at least 50% of all severe dementing conditions.
KeywordsPlacebo Dementia Neurol Acetylcholine Monoamine
Unable to display preview. Download preview PDF.
- Ahlin A, Nybäck H, Junthe T, Ahman G and Nordgren I (1991): Tetra-hydroaminoacridine in Alzheimer’s dementia: Clinical and biochemical results of a double-blind crossover trial. Human Psychopharmacol (In Press).Google Scholar
- Christie JE (1982): Physostigmine and arecoline infusions in Alzheimer’s disease. In: Alzheimer’s disease: A report of progress in research. (Aging, Vol. 19), Corkin S, Davis KL, Growdon JH, Usdin E and Wurtman RJ, eds. New York: Raven Press, pp. 413–419.Google Scholar
- Davis KL and Mohs RC (1982): Enhancement of memory processes in Alzheimer’s disease with multiple-dose intravenous physostigmine. Am J Psychiat 139:1421–1424.Google Scholar
- Minthon L, Dalfelt G, Gustafson L, Hagberg B, Nilsson K, Rosen I and Risberg J (1991): Oral tetrahydroaminoacridine (THA) and lecithin treatment of Alzheimer’s disease. (In Manuscript).Google Scholar
- Mohs RC, Davis BM, Johns CA, Mathé AA, Greenwald BS, Horvath TB and Davis KL (1985): Oral physostigmine treatment of patients with Alzheimer’s disease. Am J Psychiat 142:28–33.Google Scholar
- Nybäck H, Nyman H, Blomqvist G, Sjögren I and Stone-Elander S (1991): Brain metabolism in Alzheimer’s dementia: Studies of HC-deoxyglucose accumu-lation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects. J Neurol Neurosurg Psychiat (In Press).Google Scholar
- Nybäck H, Nyman H, Öhman G, Nordgren I and Lindström B (1988): Preliminary experiences and results with THA for the amelioration of symptoms of Alzheimer’s disease. In: Current Research in Alzheimer Therapy, Giacobini E and Becker R, eds. New York: Taylor and Francis, pp. 231–236.Google Scholar
- Risberg J, Gustafson L and Brun A (1990): High resolution regional cerebral blood flow measurements in Alzheimer’s disease and other dementia disorders. In: Alzheimer’s Disease. Epidemiology, Neuropathology, Neurochemistry and Clinics. Maurer K, Riederer P and Beckmann H, eds. Berlin: Springer-Verlag, pp. 510–516.Google Scholar
- Summers WK, Viesselman JO, Marsh GM and Candelora K (1981): Use of THA in the treatment of Alzheimer-like dementia: Pilot study in twelve patients. Biol Psychiat 16:145–153.Google Scholar